Erratum: A phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors (Investigational New Drugs (2013) 31 (742-750) DOI 10.1007/s10637-012-9881-z);A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 742-750

  Shapiro, Geoffrey I ^a   McCallum, Stewart ^b   Adams, Laurel M ^b   Sherman, Laurie ^b   Weller, Steve ^b   Swann, Suzanne ^b   Keer, Harold ^c   Miles, Dale ^c   Müller, Thomas ^c   Lorusso, Patricia ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c EXELIXIS INC   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Foretinib; GSK1363089; Multi kinase inhibitor; Solid tumors; XL880

Indexed keywords

FORETINIB; SCATTER FACTOR RECEPTOR; VASCULOTROPIN A;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INOPERABLE CANCER; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SIDE EFFECT; SOLID TUMOR; STEADY STATE; VOMITING;

EID: 84879110331     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0287-6     Document Type: Erratum

References (28)

1. Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2:289-300
2. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
3. Derksen PW, de Gorter HP, Meijer HP, et al. (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17:764-774
4. Zhang YW, Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408-417
5. Zhang YW, Su Y, Volpert OV, et al. (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100:12718-12723
6. Birchmeier C, Birchmeier W, Gherardi E, et al. (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
7. Yamashita J, Ogawa M, Yamashita S, et al. (1994) Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54:1630-1633
8. Ghoussoub RA, Dillon DA, D'Aquila T, et al. (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513-1520
9. Ueki T, Fujimoto J, Suzuki T, et al. (1997) Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25:619-623
10. Daveau M, Scotte M, Francois A, et al. (2003) Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36:130-141
11. Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645
12. Sennino B, Naylor RM, Tabruyn SP, et al. (2009) Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-TAG2 mice after inhibition of VEGFR plus C-MET by XL 184. Mol Cancer Ther 8: Abstract 13
13. Sennino B, Ishiguro-Oonuma T, Wei Y (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270-287
14. Gerritsen ME, Tomlinson JE, Zlot C, et al. (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 140:595-610
15. Xin X, Yang S, Ingle G, et al. (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158:1111-1120
16. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signaling in cancer and approaches to enforce tumour regression. Nature 441:437-443
17. Vaupel P (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl 3):21-26
18. Ye X, Li Y, Stawicki S, et al. (2010) An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29:5254-5264
19. Qian F, Engst S, Yamaguchi K, et al. (2009) Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 69:8009-8016
20. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739
21. Eder JP, Shapiro GI, Appleman LJ, et al. (2010) A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16:3507-3516
22. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available online at: http://ctep.cancer.gov/reporting/ctc.html (last accessed 21 March 2009)
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
24. van Heeckeren WJ, Ortiz J, Cooney MM, et al. (2007) Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25:2993-2995
25. Jhawer M, Kindler HL, Wainberg Z, et al. (2009) GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter Phase II study. ASCO (2009) American Society of Clinical Oncology 45th Annual Meeting. Abstract #4502
26. Seiwert T, Swann S, Kurz H, Bonate P, McCallum S, Sarantopoulos J (2009) A Phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent five days on nine days off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN). Molec Cancer Ther 8 Suppl 1:Abstract #B6. Doi: 10.1158/1535-7163. TARG-090B6.
27. Srinivasan R, Linehan M, Vaishampayan U, et al. (2009) A Phase II Study of 2 dosing regimens of foretinib (GSK 1363089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 27 Suppl 15s: Abstract #5103.
28. Yau T, Sukeepaisarnjaroen W, Chao Y, et al. (2012) A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). J Clin Oncol 30 Suppl:Abstract #4108